Experts weigh genomic testing, treatment intensification, and radioligand sequencing in advanced prostate cancer care.
Commentary|Articles|August 5, 2026
Talk of Cure, a New ADC, and a Negative Trial: Breaking Down the Biggest Gynecologic Cancer News From ASCO 2026
Author(s)Caroline Seymour
Fact checked by: Kyle Doherty , Cheney Gazzam Baltz
Top experts discuss the most important takeaways and data in ovarian and endometrial cancer to come out of this year’s ASCO annual meeting.
Advertisement
Advertisement
OncLive® connected with gynecologic oncology experts at the
Related to this article
Trine Jakobi Nøttrup, MD, PhD, discusses data for the hTERT-directed vaccine UV1 in BRCA wild-type recurrent ovarian cancer/
Experts break down key gynecologic cancer data and trends from the 2026 ESMO Congress.
Retrospective data tie longer survival with niraparib maintenance to homologous recombination deficiency after complete primary debulking.
Exploratory BEHOLD-1 data show responses to mocertatug rezetecan in platinum-resistant ovarian cancer across B7-H4 expression levels.
Updated BEHOLD-1 data show mocertatug rezetecan at its selected dose produced lasting responses in platinum-resistant ovarian cancer.
During a recent OncLive Peer Exchange, multiple myeloma experts discussed how BCMA-directed therapies can be selected and sequenced.
The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.
Advertisement
Advertisement